Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;11(4):835-844.
doi: 10.1007/s13300-020-00798-x. Epub 2020 Mar 17.

The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes

Win L Yin  1 , Steve C Bain  1   2 , Thinzar Min  3   4
Affiliations
Review

The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes

Win L Yin et al. Diabetes Ther. 2020 Apr.

Abstract

This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies.

Keywords: Chronic kidney disease; Diabetes-related nephropathy; Diabetic nephropathy; Dipeptidyl peptidase-4 (DPP-4) inhibitors; Glucagon-like peptide-1 receptor agonists; Type 2 diabetes.

PubMed Disclaimer

References

    1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. doi: 10.2215/CJN.11491116. - DOI - PMC - PubMed
    1. Hole B, et al. UK Renal Registry 19th annual report: chapter 12 multisite dialysis access audit in England, Northern Ireland and Wales in 2015 and 2014 PD one year follow-up: national and centre-specific analyses. Nephron. 2017;137(Suppl 1):269–296. doi: 10.1159/000481374. - DOI - PubMed
    1. Gregg EW, Williams DE, Geiss L. Changes in diabetes-related complications in the United States. N Engl J Med. 2014;371(3):286–287. - PubMed
    1. Vassalotti JA, Piraino B, Szczech LA. A decade after the KDOQI CKD guidelines: impact on the National Kidney Foundation. Am J Kidney Dis. 2012;60(5):689–691. doi: 10.1053/j.ajkd.2012.08.013. - DOI - PubMed
    1. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64–78. doi: 10.2337/diab.32.2.S64. - DOI - PubMed

LinkOut - more resources